Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

  • End date
    Aug 31, 2022
  • participants needed
  • sponsor
    Galderma R&D
Updated on 4 August 2021


The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.

Condition Acne Vulgaris, Acne, acnes
Treatment Trifarotene Cream, Trifarotene Vehicle Cream
Clinical Study IdentifierNCT04856904
SponsorGalderma R&D
Last Modified on4 August 2021


Yes No Not Sure

Inclusion Criteria

Participant with clinical diagnosis of acne vulgaris on the face as defined by (excluding the nose and middle zone of approximately 2 centimeter [cm])
Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), with the same score on both sides of the face; and
A minimum of 20 inflammatory lesions (papules and pustules) in total with at least 10 on each side; and
No more than 2 nodules (greater than or equal to [>=] 1 cm in diameter) on the face; and
A minimum of 10 atrophic acne scars in total (>2 mm)
Participant with a symmetrical number of the following lesions/scars on the whole
Inflammatory and non-inflammatory lesions; and
Atrophic acne scars (minimum of 4 scars per half-face)
The participant is a female of non-childbearing potential
If a female of childbearing, potential uses oral contraceptives that are also approve for treating acne vulgaris
Other protocol defined inclusion criteria could apply

Exclusion Criteria

Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne and acne requiring systemic treatment
Participant with any acne cyst on the face or with more than 3 excoriated acne lesions
Participant with known active or chronic allergies or suspected allergy to trifarotene or excipients of the formulation
Participant with facial dermal conditions (for example, tattoo, skin abrasion, eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the opinion of the investigator
Participant with known impaired hepatic or renal functions, based on medical history
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note